Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia

Br J Haematol. 2022 Mar;196(6):e71-e74. doi: 10.1111/bjh.17996. Epub 2021 Dec 21.

Authors

Amandeep Salhotra¹, Ni-Chun Tsai², Jianying Zhang², Dat Ngo³, Ahmed Aribi¹, Karamjeet Sandhu¹, Brian Ball¹, Monzr Al-Malki¹, Haris Ali¹, Paul Koller¹, Andrew Artz¹, Stephen Forman¹, Ryotaro Nakamura¹, Anthony Stein¹, Guido Marcucci¹, Ibrahim Aldoss¹, Vinod Pullarkat¹

Affiliations

¹ Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
² Department of Information Sciences, City of Hope National Medical Center, Duarte, CA, USA.
³ Department of Clinical Pharmacology, City of Hope National Medical Center, Duarte, CA, USA.

PMID: 34931310
DOI: 10.1111/bjh.17996

No abstract available

Keywords: HMA+Ven; acute myeloid leukaemia (AML).

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
Humans
Leukemia, Myeloid, Acute* / chemically induced
Leukemia, Myeloid, Acute* / drug therapy
Sulfonamides / therapeutic use

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax